Tracers / [89Zr]Nb159

[89Zr]Nb159

Also written as [Zr-89]Zr-Nb159

Radionuclide: Zr-89 t½ 4704 min
Modality: Therapy
Production route: —
Stage: Reported once
Syntheses indexed: 1

Preclinical only, no clinical indication yet Fibroblast activation / tumour stroma

What it is

Compound class: FAP-targeting nanobody (DFO-conjugated)
Target / mechanism: Fibroblast activation protein (FAP) PMID 41460404
Clinical application: —
Theranostic pair: —

Regulatory status

FDA: —
EMA (centralised): —
Other approvals: —
Brand names: —

Clinical use

Typical injected activity: —
Uptake time: —

Reported in the literature. Not a dosing recommendation.

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	SPE	81.8% yes	>97%	DFO-Nb159	41460404 2025 EJNMMI Radiopharm Chem 111 MBq of 89Zr-oxalate solution (3D Imaging) was diluted with 300 µl of 1 M HEPES and added to 200 µl of DFO-functionalized Nb (1–2 mg) in HEPES/NaCl buffer (pH 7.5), adjusted to pH 6.8–7.5, and incubated for 1 h at room temperature. — achieving a radiochemical purity > 97% and a decay-corrected yield of 81.8%

Need this precursor?We can point you to suppliers for [89Zr]Nb159, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 41460404. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 41460404: 'DFO-Nb159 and PEG-DFO-Nb159 were labeled with Zirconium-89'.